Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm INCB123667 in platinum-resistant ovarian cancer with cyclin E1 overexpression
jRCT2011250028Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of INCB123667 in high-grade serous carcinoma (HGSC), High-grade serous carcinoma of the fallopian tube (HGSC), primary peritoneal cancer (PPC) and 1 more (3 cohorts), sponsored by Incyte. Primary endpoint: Objective Response by IRC. Started Nov 2025; status: recruiting.
02
Drugs
INCB123667
03
Conditions
high-grade serous carcinoma (HGSC)High-grade serous carcinoma of the fallopian tube (HGSC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on jRCT2011250028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250028.